Acadia Pharmaceutica (ACAD)

$21.80 +0.42 (1.96%)
Market Cap 3.61B
Revenue (ttm) 957.80M
Net Income (ttm) 226.45M
EPS (ttm) N/A
PE Ratio 33.19
Forward PE 40.65
Profit Margin 23.64%
Debt to Equity Ratio 0.00
Volume 1,346,700
Avg Vol 2,096,032
Day's Range N/A - N/A
Shares Out 168.71M
Stochastic %K 40%
Beta 0.75
Analysts Strong Sell
Price Target $29.47

Company Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimava...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 558 2871
Fax: 858 212 0513
Address:
12830 El Camino Real, Suite 400, San Diego, United States
topstockalerts
topstockalerts Oct. 3 at 12:08 PM
$ACAD look who’s waking up..
0 · Reply
HorizonBull
HorizonBull Oct. 3 at 12:03 PM
$ACAD 25+ soon
0 · Reply
HorizonBull
HorizonBull Oct. 3 at 12:02 PM
$ACAD
0 · Reply
Quantumup
Quantumup Oct. 2 at 3:54 PM
BofA $TSHA Buy; $8 PT. $ACAD $AVXL BofA said: TSHA announced that FDA had granted Breakthrough Therapy designation to TSHA-102 based on the 12-patient safety and efficacy data generated from REVEAL Part A. We think the designation validates TSHA-102 as addressing a high unmet need in Rett syndrome as potentially the first disease-modifying therapy for patients. BofA additionally said: Taysha Gene Therapies (TSHA) announced finalized FDA alignment on their pivotal REVEAL Part B study, assessing one-time gene therapy, TSHA-102, in Rett syndrome. The finalized design retains the 6-month interim readout for a potential BLA filing and will enroll a target of 15 patients. Enrollment is set to begin in 4Q. TSHA states that the minimum threshold for success in the Part B study is achieving a responder rate of 33% (5/15) which we view as a manageable bar to clear as TSHA-102 achieved a 6-month 83% (5/6) responder rate at the 1E15 vg dose from Part A. We maintain our Buy rating with the same $8 PO.
0 · Reply
zeustony88
zeustony88 Oct. 2 at 3:04 PM
$ACAD https://ir.acadia.com/news-releases/news-release-details/acadia-pharmaceuticals-presents-clinical-data-across-multiple
0 · Reply
HorizonBull
HorizonBull Oct. 1 at 6:25 PM
$ACAD Added 250
0 · Reply
HorizonBull
HorizonBull Oct. 1 at 3:17 PM
$ACAD Added 250 more. should be atleast 30. price target ugraded to 35+. Q3 will be fantastic. accumulation underway
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:57 PM
$VOR Vor Biopharma: 43 trades, $13.6K vs $285K avg (0.05x). $12.4K calls / $0.001K puts. $BLND Blend Labs: 49 trades, $12.7K vs $141K avg (0.09x). $12.4K calls / $0.3K puts. $ASTX Tradr 2X Long $ASTS ETF: 21 trades, $16.8K vs $63K avg (0.26x). $12.4K calls / $4.3K puts. $ACAD Acadia Pharma: 92 trades, $16.7K vs $114K avg (0.15x). $12.4K calls / $4.3K puts.
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:04 PM
$ACAD Watch / Buy JP Morgan cuts target price to $33 from $34
0 · Reply
HorizonBull
HorizonBull Sep. 29 at 3:19 PM
$ACAD Upgrade by JPM . added 250
0 · Reply
Latest News on ACAD
Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Oct 2, 2025, 9:04 AM EDT - 2 days ago

Acadia Pharmaceuticals Presents Clinical Data from Across Multiple Therapeutic Programs at the 2025 International Congress of Parkinson's Disease and Movement Disorders®

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Sep 24, 2025, 10:05 AM EDT - 10 days ago

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Sep 24, 2025, 7:12 AM EDT - 10 days ago

Acadia Pharmaceuticals' rare disease therapy fails late-stage trial

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Sep 24, 2025, 7:00 AM EDT - 10 days ago

Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Sep 12, 2025, 4:05 PM EDT - 22 days ago

Real World Data from LOTUS Study Evaluating Long-term Efficacy and Tolerability Outcomes of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Developmental Medicine and Child Neurology

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 4:05 PM EDT - 26 days ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 4:04 PM EDT - 26 days ago

ACADIA Pharmaceuticals Inc. (ACAD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Aug 26, 2025, 4:05 PM EDT - 5 weeks ago

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

Aug 25, 2025, 4:05 PM EDT - 5 weeks ago

Acadia Pharmaceuticals Appoints Konstantina Katcheves as Senior Vice President, Chief Business and Strategy Officer

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 3:57 AM EDT - 2 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2025 Earnings Call Transcript

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Aug 5, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Aug 4, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Jul 28, 2025, 4:32 AM EDT - 2 months ago

Acadia Pharmaceuticals: ACP-101 Read-Out Is Not Fully Priced In

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Jul 23, 2025, 4:05 PM EDT - 2 months ago

Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

Jun 25, 2025, 8:00 AM EDT - 3 months ago

Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value Drivers

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Jun 9, 2025, 4:01 PM EDT - 4 months ago

U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter Patent

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Jun 5, 2025, 9:05 AM EDT - 4 months ago

Acadia Pharmaceuticals to Host R&D Day in New York City on June 25, 2025

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

May 29, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

May 27, 2025, 4:05 PM EDT - 4 months ago

Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease Franchise

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

May 19, 2025, 8:25 AM EDT - 4 months ago

These Analysts Boost Their Forecasts On Acadia Pharmaceuticals

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

May 17, 2025, 10:00 AM EDT - 5 months ago

Acadia Pharmaceuticals: Another Legal Win, ACP-101 Readout Preview

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

May 16, 2025, 1:43 PM EDT - 5 months ago

Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent Litigation

ACADIA Pharmaceuticals: Advancing On Several Fronts

May 13, 2025, 12:01 PM EDT - 5 months ago

ACADIA Pharmaceuticals: Advancing On Several Fronts

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

May 7, 2025, 8:10 PM EDT - 5 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

May 7, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

May 5, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals to Participate in the BofA Securities 2025 Health Care Conference

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Apr 23, 2025, 4:05 PM EDT - 5 months ago

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Mar 5, 2025, 9:05 AM EST - 7 months ago

Clinical Data from Open-Label DAFFODIL™ Study Evaluating Long-term Safety of DAYBUE® (trofinetide) in Patients with Rett Syndrome Published in Med

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Mar 3, 2025, 9:05 AM EST - 7 months ago

Acadia Pharmaceuticals and Saniona Announce Initial Positive Results from ACP-711 (formerly SAN711) Phase 1 Study

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Mar 2, 2025, 5:19 AM EST - 7 months ago

Acadia Pharmaceuticals Ends FY2024 On Solid Footing

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

Feb 27, 2025, 4:05 PM EST - 7 months ago

Acadia Pharmaceuticals to Participate in the TD Cowen's 45th Annual Health Care Conference

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 8:13 PM EST - 7 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q4 2024 Earnings Call Transcript

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Feb 26, 2025, 4:05 PM EST - 7 months ago

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Feb 12, 2025, 4:05 PM EST - 8 months ago

Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Jan 14, 2025, 9:05 AM EST - 9 months ago

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Jan 14, 2025, 9:00 AM EST - 9 months ago

Acadia Pharmaceuticals Submits Marketing Authorization Application to the European Medicines Agency for Trofinetide for the Treatment of Rett Syndrome

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Dec 19, 2024, 4:05 PM EST - 10 months ago

Acadia Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Dec 11, 2024, 4:05 PM EST - 10 months ago

Acadia Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Dec 9, 2024, 9:00 AM EST - 10 months ago

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Nov 27, 2024, 3:18 PM EST - 11 months ago

Acadia: Scope Of Company Goes Beyond Recent SAN711 Licensing Deal For ET

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Nov 26, 2024, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals Announces Exclusive License Agreement with Saniona for SAN711

Acadia Pharmaceuticals: Proving The Naysayers Wrong

Nov 11, 2024, 10:50 AM EST - 11 months ago

Acadia Pharmaceuticals: Proving The Naysayers Wrong

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Nov 6, 2024, 8:09 PM EST - 11 months ago

ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Nov 6, 2024, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Nov 5, 2024, 4:05 PM EST - 11 months ago

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Oct 17, 2024, 6:41 PM EDT - 1 year ago

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Oct 16, 2024, 4:07 PM EDT - 1 year ago

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

topstockalerts
topstockalerts Oct. 3 at 12:08 PM
$ACAD look who’s waking up..
0 · Reply
HorizonBull
HorizonBull Oct. 3 at 12:03 PM
$ACAD 25+ soon
0 · Reply
HorizonBull
HorizonBull Oct. 3 at 12:02 PM
$ACAD
0 · Reply
Quantumup
Quantumup Oct. 2 at 3:54 PM
BofA $TSHA Buy; $8 PT. $ACAD $AVXL BofA said: TSHA announced that FDA had granted Breakthrough Therapy designation to TSHA-102 based on the 12-patient safety and efficacy data generated from REVEAL Part A. We think the designation validates TSHA-102 as addressing a high unmet need in Rett syndrome as potentially the first disease-modifying therapy for patients. BofA additionally said: Taysha Gene Therapies (TSHA) announced finalized FDA alignment on their pivotal REVEAL Part B study, assessing one-time gene therapy, TSHA-102, in Rett syndrome. The finalized design retains the 6-month interim readout for a potential BLA filing and will enroll a target of 15 patients. Enrollment is set to begin in 4Q. TSHA states that the minimum threshold for success in the Part B study is achieving a responder rate of 33% (5/15) which we view as a manageable bar to clear as TSHA-102 achieved a 6-month 83% (5/6) responder rate at the 1E15 vg dose from Part A. We maintain our Buy rating with the same $8 PO.
0 · Reply
zeustony88
zeustony88 Oct. 2 at 3:04 PM
$ACAD https://ir.acadia.com/news-releases/news-release-details/acadia-pharmaceuticals-presents-clinical-data-across-multiple
0 · Reply
HorizonBull
HorizonBull Oct. 1 at 6:25 PM
$ACAD Added 250
0 · Reply
HorizonBull
HorizonBull Oct. 1 at 3:17 PM
$ACAD Added 250 more. should be atleast 30. price target ugraded to 35+. Q3 will be fantastic. accumulation underway
0 · Reply
highnihilism
highnihilism Sep. 30 at 12:57 PM
$VOR Vor Biopharma: 43 trades, $13.6K vs $285K avg (0.05x). $12.4K calls / $0.001K puts. $BLND Blend Labs: 49 trades, $12.7K vs $141K avg (0.09x). $12.4K calls / $0.3K puts. $ASTX Tradr 2X Long $ASTS ETF: 21 trades, $16.8K vs $63K avg (0.26x). $12.4K calls / $4.3K puts. $ACAD Acadia Pharma: 92 trades, $16.7K vs $114K avg (0.15x). $12.4K calls / $4.3K puts.
0 · Reply
IN0V8
IN0V8 Sep. 29 at 6:04 PM
$ACAD Watch / Buy JP Morgan cuts target price to $33 from $34
0 · Reply
HorizonBull
HorizonBull Sep. 29 at 3:19 PM
$ACAD Upgrade by JPM . added 250
0 · Reply
JarvisFlow
JarvisFlow Sep. 29 at 12:10 PM
JP Morgan has updated their rating for ACADIA Pharmaceuticals ( $ACAD ) to Overweight with a price target of 33.
0 · Reply
HorizonBull
HorizonBull Sep. 26 at 2:12 PM
$ACAD Cheap
0 · Reply
ZacksResearch
ZacksResearch Sep. 25 at 3:30 PM
$ACAD tumbles 9.9% — late-stage failure in PWS drug study ACP-101 falls short in phase III trial, failing to outperform placebo in hyperphagia treatment. With ACAD halting further development, Soleno’s Vykat XR, already FDA-approved, maintains its market position. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2757116/acad-stock-down-10-following-phase-iii-hyperphagia-study-failure?cid=sm-stocktwits-2-2757116-body-14127&ADID=SYND_STOCKTWITS_TWEET_2_2757116_BODY_14127
0 · Reply
ZacksResearch
ZacksResearch Sep. 25 at 2:30 PM
$ACAD just cratered 10% — but is this a buy-the-dip? The phase III hyperphagia study failed, sparking the selloff, yet Nuplazid, Daybue, and a strong pipeline still anchor the growth story. Full bull/bear case on ACAD 👉 https://www.zacks.com/stock/news/2757116/acad-stock-down-10-following-phase-iii-hyperphagia-study-failure?cid=sm-stocktwits-2-2757116-teaser-14120&ADID=SYND_STOCKTWITS_TWEET_2_2757116_TEASER_14120
0 · Reply
highnihilism
highnihilism Sep. 24 at 7:09 PM
Russell 2000 (Healthcare) → $ACHC Acadia Healthcare $ACAD ACADIA Pharmaceuticals $AMED Amedisys $ANIP ANI Pharmaceuticals $ATRC AtriCure
0 · Reply
mcollins4
mcollins4 Sep. 24 at 6:57 PM
$ACAD Nice bounce back
0 · Reply
HorizonBull
HorizonBull Sep. 24 at 5:23 PM
$ACAD Opportunity to load cheap. this was expected
0 · Reply
BioTechHealthX
BioTechHealthX Sep. 24 at 4:29 PM
$ACAD Acadia’s COMPASS PWS study of intranasal carbetocin missed primary & secondary endpoints, forcing the company to abandon ACP-101 development. https://biotechhealthx.com/biotech-news/acadia-pharmaceuticals-acads-phase-3-trial-fails/
0 · Reply
Rickster4retirement
Rickster4retirement Sep. 24 at 3:39 PM
$ACAD Here we go again. 😑
0 · Reply
theflynews
theflynews Sep. 24 at 2:55 PM
Soleno shares jump following competitor Acadia’s trial miss - $ACAD - https://thefly.com/permalinks/entry.php/ACADid4202519?1758725226C38
0 · Reply
HorizonBull
HorizonBull Sep. 24 at 2:33 PM
$ACAD Added 500 more
1 · Reply
GI197845
GI197845 Sep. 24 at 2:17 PM
$ACAD Well obviously, the failure of Hyperphagia in Prader-Willi Syndrome sucks for those with the disease and and Acadia investors. However, Acadia under better management now and the fact the they released this failure soon, is a good sign in my opinion, because they did not fraudulently deceive investors long term. Do not be surprised, if there is an over reaction due to this failure, which could be a buying opportunity. Also, do not be surprised if the improved management suddenly announces they bought a new med from Stoke's or something like that, that could boost the stock price.
0 · Reply